Komori
Financial results presentation4507Shionogi & Co.,Ltd.Pharmaceuticals

FY2026 Second-Quarter (First-Half) Results Briefing Materials

For the first half of FY2026, revenue and all profit items exceeded first-half forecasts, resulting in substantial year-on-year increases in both revenue and profit. In light of strong progress in the core businesses, full-year forecasts for revenue, operating profit and profit attributable to owners of the parent, among other items, were revised upward.

Worth reading
78Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
200
¥100 million (full-year revenue forecast revision)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial results presentationFY2026 second quarter (interim period)12 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,504 100 million+64.5%
Operating profit¥1,152 100 million+55.8%
Ordinary income¥1,073 100 million +9.9%interim profit before tax
Net income¥1,195 100 million +44.0%interim profit attributable to owners of the parent
Gross Profit Margin81.8
Operating profit margin32.9
Selling, general and administrative expenses¥1,206 100 million
Results for the three months of the current quarter
First quarter
Revenue¥1,633 100 million
Operating profit¥513 100 million
Second quarter
Revenue¥1,871 100 million
Operating profit¥640 100 million
Full-year earnings forecast
Revenue
¥7,200 100 million
Operating profit
¥2,300 100 million
Pretax profit
¥2,205 100 million
Profit for the period attributable to owners of the parent
¥2,125 100 million
EBITDA
¥3,360 100 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
First-half revenue103.1
First-half operating profit120
First-half interim profit before income taxes111.7
First-half interim profit attributable to owners of the parent110.7
Revenue by BusinessDomestic prescription pharmaceuticals 93.0%, overseas subsidiaries and exports 111.2%, contract manufacturing 86.5%, OTC pharmaceuticals 93.4%, royalty income 104.9%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Exceeded the first-half forecast
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in revenue¥137.4 billion
  • Increase in costs of sales¥33.9 billion
  • Higher SG&A expenses¥66.2 billion
  • Increase in R&D expenses¥15 billion
  • Increase in other income and expenses¥18.9 billion
  • Decrease in finance income and expenses-¥31.6 billion
  • Increase in operating profit¥41.3 billion
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Dollar¥159.0 (period average)
Pound¥213.4 (period average)
Euro¥184.4 (period average)
New initiatives
  • Acquisition of IntraBio (transaction expected to close: November–December 2026)
  • Expansion of AQNEURSA sales in the US and Europe
  • Sale of the subsidiary responsible for the generic pharmaceuticals business in China
  • Development of an HIV treatment administered 3 times a year
  • Development of an HIV treatment administered 2 times a year
  • Development of an HIV preventive treatment administered 3 times a year
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥1,746 100 million
    Year on year against the same period last year+103.4%
  • LAI treatment sales (CY2026 Q3)£478 million
    Year on year against the same period last year+35.0%
  • LAI preventive treatment sales (CY2026 Q3)£143 million
    Year on year against the same period last year+21.0%
  • IntraBio sales scale (fiscal year ended December 2025)68 USD million
  • IntraBio employee count60 people
Segment results
  • Prescription Medicines in Japan
    Sales¥7.43 billion
    Year on year against the same period last year101.7%
  • Overseas Subsidiaries and Exports
    Sales¥95.0 billion
    Year on year against the same period last year210.2%
  • Contract development and manufacturing
    Sales¥6.6 billion
    Year on year against the same period last year△6.7%
  • Over-the-counter medicines
    Sales¥7.8 billion
    Year on year against the same period last year△1.0%
  • Royalty income
    Sales¥165.4 billion
    Year on year against the same period last year27.9%
  • Other
    Sales¥1.2bn
    Year on year against the same period last year2.4%
Financial targets
DOE target4% or higher
ROEFY2026 forecast not disclosed
Actual DOE4.2% (forecast)
Market Size / Share
NPC incidence: approximately 1 in 100,000 people; approximately 400 diagnosed patients in the US and approximately 500 in 5 European countries. A-T incidence: approximately 1 in 40,000 to 100,000 people; approximately 1,500 diagnosed patients in the US and approximately 800 in 5 European countries
Number of employees
IntraBio employee count: approximately 60
Capital expenditures
¥7,200 billions business investment and capital investment plans
Annual Dividend
Annual¥86 (planned)
InterimAnnual dividend per share: ¥46 (forecast)
End of period¥40 (planned)
Acquisition of treasury shares
Plans to implement purchases flexibly. Purchase amount, number of shares and period: Not disclosed
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFY2026 second quarter (interim period)
Net Sales¥3,504 100 million (YoY +64.5%)
Operating profit¥1,152 100 million (YoY +55.8%)
Ordinary income¥1,073 100 million (interim profit before tax) (YoY +9.9%)
Net income¥1,195 100 million (interim profit attributable to owners of the parent) (YoY +44.0%)
Gross Profit Margin81.8
Operating profit margin32.9
Selling, general and administrative expenses¥1,206 100 million
Results for the three months of the current quarterFirst quarter Revenue ¥1,633 100 million / Operating profit ¥513 100 million / Second quarter Revenue ¥1,871 100 million / Operating profit ¥640 100 million
Full-year earnings forecastRevenue ¥7,200 100 million / Operating profit ¥2,300 100 million / Pretax profit ¥2,205 100 million / Profit for the period attributable to owners of the parent ¥2,125 100 million / EBITDA ¥3,360 100 million
Progress against full-year forecastFirst-half revenue 103.1 / First-half operating profit 120 / First-half interim profit before income taxes 111.7 / First-half interim profit attributable to owners of the parent 110.7 / Revenue by Business Domestic prescription pharmaceuticals 93.0%, overseas subsidiaries and exports 111.2%, contract manufacturing 86.5%, OTC pharmaceuticals 93.4%, royalty income 104.9%
Self-assessment against the planExceeded the first-half forecast
Segment resultsSegment Prescription Medicines in Japan / Sales ¥7.43 billion / Year on year against the same period last year 101.7%, Segment Overseas Subsidiaries and Exports / Sales ¥95.0 billion / Year on year against the same period last year 210.2%, Segment Contract development and manufacturing / Sales ¥6.6 billion / Year on year against the same period last year △6.7%, Segment Over-the-counter medicines / Sales ¥7.8 billion / Year on year against the same period last year △1.0%, Segment Royalty income / Sales ¥165.4 billion / Year on year against the same period last year 27.9%, Segment Other / Sales ¥1.2bn / Year on year against the same period last year 2.4%
Breakdown of Factors Affecting the ChangeItem Increase in revenue / Amount ¥137.4 billion, Item Increase in costs of sales / Amount ¥33.9 billion, Item Higher SG&A expenses / Amount ¥66.2 billion, Item Increase in R&D expenses / Amount ¥15 billion, Item Increase in other income and expenses / Amount ¥18.9 billion, Item Decrease in finance income and expenses / Amount -¥31.6 billion, Item Increase in operating profit / Amount ¥41.3 billion
Key KPIsIndicator EBITDA / Value ¥1,746 100 million / Year on year against the same period last year ¥103.4 100 million, Indicator LAI treatment sales (CY2026 Q3) / Value £478 million / Year on year against the same period last year £35 million, Indicator LAI preventive treatment sales (CY2026 Q3) / Value £143 million / Year on year against the same period last year £21 million, Indicator IntraBio sales scale (fiscal year ended December 2025) / Value 68 USD million / Year on year against the same period last year Not disclosed, Indicator IntraBio employee count / Value 60 people / Year on year against the same period last year Not disclosed
Number of employeesIntraBio employee count: approximately 60
Assumptions Underlying the Business OutlookDollar ¥159.0 (period average) / Pound ¥213.4 (period average) / Euro ¥184.4 (period average)
Financial targetsDOE target 4% or higher / ROE FY2026 forecast not disclosed / Actual DOE 4.2% (forecast)
Annual DividendAnnual ¥86 (planned) / Interim Annual dividend per share: ¥46 (forecast) / End of period ¥40 (planned)
Acquisition of treasury sharesPlans to implement purchases flexibly. Purchase amount, number of shares and period: Not disclosed
Capital expenditures¥7,200 billions (business investment and capital investment plans)
Market Size / ShareNPC incidence: approximately 1 in 100,000 people; approximately 400 diagnosed patients in the US and approximately 500 in 5 European countries. A-T incidence: approximately 1 in 40,000 to 100,000 people; approximately 1,500 diagnosed patients in the US and approximately 800 in 5 European countries
New initiativesAcquisition of IntraBio (transaction expected to close: November–December 2026), Expansion of AQNEURSA sales in the US and Europe, Sale of the subsidiary responsible for the generic pharmaceuticals business in China, Development of an HIV treatment administered 3 times a year, Development of an HIV treatment administered 2 times a year, Development of an HIV preventive treatment administered 3 times a year
Items this document does not state (7)
Unit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsPayout ratioOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased in the first half, driven by higher royalty income, domestic prescription pharmaceuticals, and overseas subsidiaries and exports. Profit increased due to higher sales at Torii Pharmaceutical and the results of growth investments. The upward revision to the full-year forecasts reflects strong progress by Cabenuva, Torii Pharmaceutical-related products, Shionogi Inc. and Shionogi B.V., cefiderocol, and ViiV's HIV franchise.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
FY2026 Second-Quarter (First-Half) Results Briefing Materials | Shionogi & Co.,Ltd. (4507) timely disclosure | Komori